Very low dose naltrexone addition in opioid detoxification: A randomized, controlled trial

Addiction Biology

Volumn 14, Issue 2, 2009, Pages 204-213

  Mannelli, Paolo ^a   Patkar, Ashwin A ^a   Peindl, Kathi ^a   Gorelick, David A ^b   Wu, Li Tzy ^a   Gottheil, Edward ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Community treatment programs; Craving; Opioid agonist antagonist interaction; Opioid antagonist; Opioid dependence; Opioid withdrawal

Indexed keywords

CHLORDIAZEPOXIDE; CLONIDINE; CYCLOBENZAPRINE; IBUPROFEN; LOPERAMIDE; METHADONE; NALTREXONE; OLANZAPINE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; PARACETAMOL; PLACEBO;

ADULT; AGITATION; ANXIETY; ANXIETY DISORDER; ARTICLE; BONE PAIN; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERGLYCEMIA; LOW DRUG DOSE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SWEATING; SYSTOLIC BLOOD PRESSURE; WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; COMMUNITY MENTAL HEALTH SERVICES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; MALE; METABOLIC DETOXICATION, DRUG; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PROGRAM DEVELOPMENT; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 61849181610     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2008.00119.x     Document Type: Article

References (49)

1. Amato L, Davoli M, Ferri M, Gowing L, Perucci CA (2004) Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug Alcohol Depend 73 : 219 226.
2. Amato L, Davoli M, Minozzi S, Ali R, Ferri M (2005) Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 20 : CD003409.
3. American Psychiatric Association (2000) Diagnostic criteria from DSM-IV-TR / American Psychiatric Association. Washington, D.C.
4. Armenian SH, Chutuape MA, Stitzer ML (1999) Predictors of discharges against medical advice from a short-term hospital detoxification unit. Drug Alcohol Depend 56 : 1 8.
5. Blondell RD, Amadasu A, Servoss TJ, Smith SJ (2006) Differences among those who complete and fail to complete inpatient detoxification. J Addict Dis 25 : 95 104.
6. Broers B, Giner F, Dumont P, Mino A (2000) Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug Alcohol Depend 58 : 85 92.
7. Burns LH (2005) Ultra-low-dose opioid antagonists enhance opioid analgesia while reducing tolerance, dependence and addictive properties. In : Capasso A, ed. Recent developments in Pain Research, pp. 115 136. Kerala : Trivandrum.
8. Buydens-Branchey L, Branchey M, Reel-Brander C (2005) Efficacy of buspirone in the treatment of opioid withdrawal. J Clin Psychopharmacol 25 : 230 236.
9. Charney DS, Riordan CE, Kleber HD, Murburg M, Braverman P, Sternberg DE, Heninger GR, Redmond DE (1982) Clonidine and naltrexone: a safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy. Arch Gen Psychiatry 39 : 1327 1332.
10. Chutuape MA, Jasinski DR, Fingerhood MI, Stitzer ML (2001) One-, three-, and six-month outcomes after brief inpatient opioid detoxification. Am J Drug Alcohol Abuse 27 : 19 44.
11. Cohen J (1988) Statistical Power Analyses for the Social Science. New York : Lawrence, Erlbaum & Associates.
12. Collins ED, Kleber HD, Whittington RA, Heitler NE (2005) Anesthesia-assisted vs. buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA 294 : 903 913.
13. Crain SM, Shen KF (2001) Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res 888 : 75 82.
14. De Jong CA, Laheij RJ, Krabbe PF (2005) General anaesthesia does not improve outcome in opioid antagonist detoxification treatment: a randomized controlled trial. Addiction 100 : 206 215.
15. Gossling HW, Gunkel S, Schneider U, Melles W (2001) Frequency and causes of premature termination (drop-out) during in-patient opiate detoxification. Fortschr Neurol Psychiatr 69 : 474 481.
16. Gossop M, Green L, Phillips G, Bradley B (1987) What happens to opiate addicts immediately after treatment: a prospective follow-up study. BMJ 294 : 1377 1380.
17. Gowing L, Ali R (2006) The place of detoxification in treatment of opioid dependence. Curr Opin Psychiatry 19 : 3 266 270.
18. Gowing L, Ali R, White J (2004) Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 18 : CD002025.
19. Gowing L, Ali R, White J (2006) Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database Syst Rev 19 : CD002022.
20. Gracy KN, Dankiewicz LA, Koob GF (2001) Opiate withdrawal-induced fos immunoreactivity in the rat extended amygdala parallels the development of conditioned place aversion. Neuropsychopharmacol 24 : 152 160.
21. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD (1987) Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 13 : 293 308.
22. Herman I, Shamir D, Bar-Hamburger R, Pick CG, Schreiber S (2005) The effect of mianserin add-on, on the intensity of opioid withdrawal symptoms during detoxification program - a randomized, double blind, placebo controlled, prospective study. Addict Behav 30 : 1154 1167.
23. Huang B, Dawson DA, Stinson FS, Hasin DS, Ruan WJ, Saha TD, Smith SM, Goldstein RB, Grant BF (2006) Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: results of the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 67 : 1062 1073.
24. Jaffe JH (2006) Do antagonists have a role in the treatment of opioid dependence? Addiction 101 : 468 469.
25. Kanof PD, Handelsman L, Aronson MJ, Ness R, Cochrane KJ, Rubinstein KJ (1992) Clinical characteristics of naloxone-precipitated withdrawal in human opioid-dependent subjects. J Pharmacol Exp Ther 260 : 355 363.
26. Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T (1987) Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 13 : 1 17.
27. Lucas GM (2004) Buprenorphine in primary HIV care clinics: a big pill to swallow. Hopkins HIV Rep 16 : 5 7.
28. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M (1992) The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 9 : 199 213.
29. McLellan AT, Woody GE, Metzger D, McKay J, Durrell J, Alterman AI, O'Brien CP (1996) Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. Milbank Q 74 : 51 85.
30. Mannelli P, Gottheil E, Buonanno A, De Risio S (2003) Use of very low-dose naltrexone during opiate detoxification. J Addict Dis 22 : 63 70.
31. Mannelli P, Gottheil E, Peoples JF, Oropeza VC, Van Bockstaele EJ (2004) Chronic very low dose naltrexone administration attenuates opioid withdrawal expression. Biol Psychiatry 56 : 261 268.
32. Mannelli P, Gottheil E, Van Bockstaele EJ (2006) Antagonist treatment of opioid withdrawal translational low dose approach. J Addict Dis 25 : 1 8.
33. Mattick RP, Breen C, Kimber J, Davoli M (2003) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2 : CD002209.
34. National Consensus Development Panel on Effective Medical Treatment of Opioid Addiction (1998) Effective medical treatment of opiate addiction. JAMA 280 : 1936 1943.
35. Nestler EJ, Alreja M, Aghajanian GK (1994) Molecular and cellular mechanisms of opiate action: studies in the rat locus coeruleus. Brain Res Bull 35 : 521 528.
36. O'Connor PG, Kosten TR (1998) Rapid and ultrarapid opioid detoxification techniques. JAMA 279 : 229 234.
37. Oreskovich MR, Saxon AJ, Ellis ML, Malte CA, Reoux JP, Knox PC (2005) A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug Alcohol Depend 77 : 71 79.
38. Perez de los Cobos J, Trujols J, Ribalta E, Casas M (1997) Cocaine use immediately prior to entry in an inpatient heroin detoxification unit as a predictor of discharges against medical advice. Am J Drug Alcohol Abuse 23 : 267 279.
39. Powell KJ, Abul-Husn NS, Jhamandas A, Olmstead MC, Beninger RJ, Jhamandas K (2002) Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther 300 : 588 596.
40. Rea F, Bell JR, Young MR, Mattick RP (2004) A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug Alcohol Depend 75 : 79 88.
41. Reed LJ, Glasper A, de Wet CJ, Bearn J, Gossop M (2007) Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients? J Clin Psychopharmacol 27 : 188 192.
42. Riordan CE, Kleber HD (1980) Rapid opiate detoxification with clonidine and naloxone. Lancet 1 : 1079 1080.
43. Shen KF, Crain SM (1997) Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res 757 : 176 190.
44. Srisurapanont M, Jarusuraisin N (2005) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 25 : CD001867.
45. Substance Abuse and Mental Health Services Administration (2007a) Treatment Episode and Data Set Highlights-2005. Rockville, MD : Office of Applied Studies.
46. Substance Abuse and Mental Health Services Administration (2007b) DASIS Report: Heroin Trends-Changes in How it is Used 1995-2005. Rockville, MD : Office of Applied Studies.
47. Van Bockstaele EJ, Rudoy C, Mannelli P, Oropeza V, Qian Y (2006) Elevated mu-opioid receptor expression in the nucleus of the solitary tract accompanies attenuated withdrawal signs after chronic low dose naltrexone in opiate-dependent rats. J Neurosci Res 83 : 508 514.
48. Wang HY, Friedman E, Olmstead MC, Burns LH (2005) Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 135 : 247 261.
49. Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N (2006) Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 7 : 937 946.